Skip to main content
TAIKO PHARMACEUTICAL CO., LTD. logo

TAIKO PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 4574 ISIN · JP3442200006 T Manufacturing
Open in API
Filings indexed 64 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country JP Japan
Listing T 4574

About TAIKO PHARMACEUTICAL CO., LTD.

https://www.seirogan.co.jp/en/

Taiko Pharmaceutical Co., Ltd. is a pharmaceutical company that manufactures and sells over-the-counter (OTC) medicines and infection control products. The company specializes in gastrointestinal remedies, with its flagship product, Seirogan, being a long-standing treatment for conditions such as diarrhea, loose stools, and symptoms of food and water poisoning. Its product portfolio also includes other general-use pharmaceuticals and quasi-drugs. Alongside its core pharmaceutical business, Taiko Pharmaceutical is engaged in the development and marketing of sanitation and infection management solutions. The company operates on the principles of Independence, Interdependence, and Creativity, serving both domestic and international markets.

Recent filings

Filing Released Lang Actions
臨時報告書
Regulatory Filings Classification · 80% confidence The document is a Japanese "臨時報告書" (Timely Report) filed under the Financial Instruments and Exchange Act, disclosing a significant event (receipt of dividends from a subsidiary). It is not a periodic report (annual or interim), not an earnings release, not a shareholder vote result, nor a proxy or remuneration statement. It is a one‐off regulatory disclosure required by law. Therefore it falls under the fallback category for miscellaneous regulatory filings (RNS).
2026-04-24 Japanese
連結子会社からの配当金受領に関するお知らせ
Regulatory Filings
2026-04-24 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is titled '確認書' (Confirmation Letter) and explicitly references '金融商品取引法第24条の４の２第１項' (Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act). It is a formal certification by the CEO regarding the accuracy of the Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a report, should be classified as Regulatory Filings (RNS). FY 2025
2026-03-24 Japanese
有価証券報告書－第80期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuuka Shouken Houkokusho' (Annual Securities Report), which is the Japanese equivalent of a 10-K. It contains the standard cover page with the filing date (2026-03-24), the fiscal year (2025-01-01 to 2025-12-31), and extensive XBRL-tagged financial data, confirming it is the full annual report rather than an announcement or summary. FY 2025
2026-03-24 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically related to the 'Second Quarter Report' (Dai-ni shihanki hokokusho). While it references the quarterly report, this specific document is a formal confirmation of the accuracy of the report's contents, which is a standard regulatory filing requirement in Japan. Since it is a specific regulatory filing that does not fit into the primary financial report categories (like 10-K or IR) and is not merely an announcement of a report, it falls under the general regulatory filings category.
2025-08-08 Japanese
半期報告書－第80期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '第２四半期報告書' (Second Quarter Report) for Taiko Pharmaceutical Co., Ltd., covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial statements, management analysis, and audit information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-08 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.